# Adjuvant Intensification for LAR

Source: https://onco.cc/trials/nct07407517/  
OnCo record `nct07407517` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

Adjuvant Intensification for LAR is a phase 3, randomised interventional study registered as NCT07407517 by Fudan University, with a registry enrolment figure of 904 participants, started 2026-02-01 and due to reach its primary completion in 2033-02-01. Interventions recorded: Everolimus 10 mg daily. Conditions listed: Breast Cancer Females; Triple Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Histologically confirmed invasive triple-negative breast cancer (\*\*definition\*\*: breast cancer with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) all confirmed negative by pathology". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: POLARIS
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07407517
- Phase: 3
- Setting: Standard Chemotherapy Plus Oral Everolimus as Adjuvant Therapy for LAR Breast Cancer Patients: A Randomized, Open-Label, Phase III Trial （POLARIS）
- Sponsor: Fudan University
- Enrolled: 904

## Sources

- ClinicalTrials.gov NCT07407517: https://clinicaltrials.gov/study/NCT07407517

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07407517.json